El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Design Therapeutics Inc
Cerrado
10.94 0.09
Resumen
Variación precio
24h
Mínimo
10.25
Máximo
11.08
Ingresos | 1M -16M |
|---|---|
Empleados | 54 |
EBITDA | -6M -23M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +41.04% upside |
Próximas Ganancias | 5 may 2026 |
|---|
Capitalización de Mercado | 43M 626M |
|---|---|
Apertura anterior | 10.85 |
Cierre anterior | 10.94 |
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
Design Therapeutics Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Design Therapeutics Inc Esperado
Precio Objetivo
By TipRanks
41.04% repunte
Estimación a 12 meses
Media 15.5 USD 41.04%
Máximo 18 USD
Mínimo 14 USD
De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Design Therapeutics Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Design Therapeutics Inc
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Live chat